← Back to Search

Histone Deacetylase Inhibitor

LBH589 plus Rituximab for Non-Hodgkin's Lymphoma

Phase 2
Waitlist Available
Led By Sarit Assouline, MD
Research Sponsored by Sarit Assouline
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Pathological confirmation of any stage of DLBCL. Patients with transformation to DLBCL will be permitted on study.
Patients must have received at least 1 prior line of treatment if not eligible for an autologous stem cell transplant (ASCT) or 2 prior therapies, one of which must have been an ASCT, if eligible for such therapy.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

The purpose of the study is to examine both efficacy of LBH589 in treating relapsed and refractory DLBCL, and added benefit of combining rituximab with LBH589 in this setting. Tissue samples from accessible lymph nodes will be collected and banked before the start of the study treatment and after 15 days. Additionally, blood samples will be drawn and stored in the tissue biobank.

Eligible Conditions
  • Non-Hodgkin's Lymphoma

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Efficacy of LBH589 alone and when given in combination with rituximab
Secondary outcome measures
Identify potential biological factors that might correlate with efficacy
Safety and tolerability of single agent LBH589 therapy and combination therapy of LBH589 with rituximab

Trial Design

2Treatment groups
Experimental Treatment
Group I: LBH589 plus RituximabExperimental Treatment2 Interventions
Group II: LBH589Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rituximab
FDA approved
Panobinostat
FDA approved

Find a Location

Who is running the clinical trial?

Sarit AssoulineLead Sponsor
2 Previous Clinical Trials
187 Total Patients Enrolled
NovartisIndustry Sponsor
1,609 Previous Clinical Trials
2,717,884 Total Patients Enrolled
Quebec Clinical Research Organization in CancerOTHER
3 Previous Clinical Trials
91 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby Mar 2025